🔵 RENAL CELL CARCINOMA (RCC) - Complete Overview

Sources: Campbell-Walsh-Wein Urology (9780323546423), Robbins & Kumar Basic Pathology (9780323790185), NKF Primer on Kidney Diseases (9780323791229)

📌 MASTER FLOWCHART

╔══════════════════════════════════════════════════════════════════╗
║              RENAL CELL CARCINOMA (RCC)                         ║
╚══════════════════════════════════════════════════════════════════╝
         │
         ├──► 1. ETIOLOGY & RISK FACTORS
         │
         ├──► 2. HISTOPATHOLOGICAL FEATURES
         │
         ├──► 3. CLINICAL PRESENTATION
         │
         ├──► 4. DIAGNOSTIC MODALITIES
         │
         ├──► 5. TREATMENT OPTIONS
         │
         └──► 6. PROGNOSIS & LONG-TERM OUTCOMES

🔴 1. ETIOLOGY & RISK FACTORS

RISK FACTORS FOR RCC
│
├── MODIFIABLE
│   ├── Cigarette Smoking ──────► Doubles risk; dose-dependent
│   ├── Obesity (BMI > 30) ─────► Increases risk (adipokines, sex hormones)
│   ├── Hypertension ───────────► Independent risk factor
│   ├── Cadmium/asbestos exposure (occupational)
│   └── Dialysis-associated polycystic kidney disease ──► 30× increased risk
│
├── NON-MODIFIABLE
│   ├── Age: Peak 55-75 years
│   ├── Sex: Male:Female = 1.9:1
│   ├── Race: Higher in African-Americans (+5-10%); lower in Asians (-50%)
│   └── Familial/Hereditary (4-6% of cases)
│
└── HEREDITARY SYNDROMES
    ├── Von Hippel-Lindau (VHL) disease ──► Bilateral clear cell RCC in 40-60%
    │   └── Autosomal dominant; VHL gene mutation on chromosome 3p25
    ├── Hereditary Papillary RCC ──────────► MET gene mutation (chr 7q)
    ├── Birt-Hogg-Dubé syndrome ───────────► FLCN gene; chromophobe RCC
    └── Hereditary Leiomyomatosis RCC ─────► FH gene mutation

• VHL gene loss → HIF accumulates → VEGF overexpression → tumor angiogenesis
• This is the main driver of clear cell RCC (most common subtype)

• Campbell-Walsh-Wein Urology, p. 2846-2848; Robbins & Kumar Basic Pathology, p. 531

🟠 2. HISTOPATHOLOGICAL FEATURES

RCC SUBTYPES (Based on WHO Classification)
│
├── CLEAR CELL RCC ──────────────────────────────── 65% of cases
│   ├── Origin: Proximal convoluted tubule
│   ├── Molecular: VHL gene loss (chr 3p25); HIF pathway activation
│   ├── Macro: Golden-yellow tumor (lipid-rich cells); hemorrhage & necrosis
│   ├── Micro: Cells with CLEAR cytoplasm (glycogen + lipid)
│   │         Arranged in nests/alveoli; delicate vascular network
│   ├── Grading: Fuhrman/ISUP nuclear grade I-IV
│   └── Behavior: Most aggressive; metastasizes to lung, liver, bone, brain
│
├── PAPILLARY RCC ───────────────────────────────── 10-15% of cases
│   ├── Origin: Distal tubule
│   ├── Molecular: MET gene activation (chr 7q); trisomy 7 and 17
│   ├── Macro: Bilateral/multifocal; yellow-orange; hemorrhage/necrosis
│   ├── Micro: Papillary structures with fibrovascular cores
│   │         Type 1 (low grade): small cells, pale cytoplasm
│   │         Type 2 (high grade): large cells, eosinophilic cytoplasm
│   └── Behavior: Better prognosis than clear cell
│
├── CHROMOPHOBE RCC ─────────────────────────────── 5% of cases
│   ├── Origin: Cortical collecting duct
│   ├── Molecular: Loss of multiple chromosomes (1,2,6,10,13,17,21)
│   ├── Macro: Well-circumscribed; pale tan/beige
│   ├── Micro: Large cells with PALE, fine-reticular cytoplasm
│   │         "Plant cell" appearance; prominent cell membranes
│   │         Hale's colloidal iron stain POSITIVE
│   └── Behavior: Best prognosis among all subtypes
│
├── COLLECTING DUCT (BELLINI) RCC ──────────────── <1% of cases
│   └── Very aggressive; tubular/papillary pattern; desmoplastic stroma
│
└── UNCLASSIFIED RCC ──────────────────────────── 1-5%
    └── Aggressive; often sarcomatoid differentiation; poor prognosis

• Can occur in ANY subtype
• Indicates high-grade transformation
• Associated with very poor prognosis

• Robbins & Kumar Basic Pathology, p. 531-532; Campbell-Walsh-Wein Urology, p. 2856-2860

🟡 3. CLINICAL PRESENTATION

CLINICAL PRESENTATION OF RCC
│
├── INCIDENTAL (>60% today)
│   └── Found on CT/US done for unrelated reason
│       ├── Usually organ-confined
│       └── Better prognosis
│
├── CLASSIC TRIAD ("Too Late Triad") ── now seen in <10%
│   ├── Flank pain
│   ├── Gross hematuria
│   └── Palpable abdominal mass
│   → Almost always indicates ADVANCED disease
│
├── SIGNS OF LOCAL/REGIONAL DISEASE
│   ├── Hematuria (most common symptom)
│   ├── Flank pain (hemorrhage into tumor or clot obstruction)
│   ├── Non-reducing varicocele (esp. right-sided) ── venous invasion
│   ├── Bilateral lower limb edema ─── IVC obstruction
│   └── Perinephric hematoma (spontaneous)
│
├── SIGNS OF SYSTEMIC/METASTATIC DISEASE
│   ├── Bone pain (skeletal metastases)
│   ├── Persistent cough (pulmonary metastases - most common site)
│   ├── Cervical lymphadenopathy
│   └── Constitutional: weight loss, fever, night sweats
│
└── PARANEOPLASTIC SYNDROMES (unique to RCC)
    ├── Stauffer syndrome ─── Non-metastatic hepatic dysfunction
    ├── Hypercalcemia ──────── PTHrP secretion (~10-20%)
    ├── Polycythemia ──────────Ectopic EPO secretion
    ├── Hypertension ──────────Ectopic renin production
    ├── Cushing syndrome ──────Ectopic ACTH
    └── Anemia of chronic disease

• Campbell-Walsh-Wein Urology, p. 2863-2864

🟢 4. DIAGNOSTIC MODALITIES

DIAGNOSIS OF RCC
│
├── STEP 1: INITIAL WORKUP
│   ├── Urinalysis (hematuria)
│   ├── CBC, BMP, LFTs, Serum calcium
│   ├── LDH, alkaline phosphatase, ESR, CRP
│   └── Urine cytology (if urothelial Ca suspected)
│
├── STEP 2: IMAGING
│   │
│   ├── ULTRASOUND (First-line screening)
│   │   ├── Distinguishes solid vs cystic mass
│   │   ├── Low sensitivity for small tumors
│   │   └── CEUS: avid early enhancement + early washout in clear cell
│   │
│   ├── CT SCAN (Gold Standard)
│   │   ├── Multiphasic contrast CT (corticomedullary + nephrographic phases)
│   │   ├── Clear cell: avid enhancement in corticomedullary phase
│   │   │              then hypoenhancing in nephrographic phase
│   │   ├── Papillary: hypoenhancing on ALL phases; hypointense on T2
│   │   ├── Chromophobe: avid enhancement (less than clear cell)
│   │   └── Also evaluates vascular extension, lymph nodes, staging
│   │
│   ├── MRI
│   │   ├── Equivalent to CT for characterization
│   │   ├── Superior for: IVC thrombus extent, cystic masses
│   │   ├── Better detection of complex cyst features (subtraction imaging)
│   │   └── Preferred if contrast allergy or renal impairment
│   │
│   └── BOSNIAK CLASSIFICATION (Cystic masses)
│       ├── Category I/II → Benign (follow-up only)
│       ├── Category IIF → Follow-up with repeat imaging
│       ├── Category III → Indeterminate; surgical excision recommended
│       └── Category IV → Clearly malignant → Surgery
│
├── STEP 3: BIOPSY (Selected cases)
│   ├── CT/US-guided renal mass biopsy
│   ├── Indicated when: ablative therapy planned, metastatic workup,
│   │                   lymphoma/mets suspected, small indeterminate masses
│   └── NOT mandatory before surgical resection in classic cases
│
└── STEP 4: STAGING WORKUP
    ├── CT chest/abdomen/pelvis (for metastases)
    ├── Bone scan (only if bone pain or elevated ALP)
    ├── Brain MRI (only if neurologic symptoms)
    └── TNM STAGING (AJCC 8th Ed)
        ├── T1a: ≤4 cm, confined to kidney
        ├── T1b: 4-7 cm, confined to kidney
        ├── T2a: 7-10 cm, confined to kidney
        ├── T2b: >10 cm, confined to kidney
        ├── T3a: Renal vein/perinephric fat invasion
        ├── T3b: IVC below diaphragm
        ├── T3c: IVC above diaphragm / pericardium
        ├── T4: Beyond Gerota's fascia / adrenal invasion
        ├── N1: Regional lymph node metastasis
        └── M1: Distant metastasis

Coronal contrast MRI showing bilateral large renal masses - National Kidney Foundation Primer on Kidney Diseases

• NKF Primer on Kidney Diseases, p. 78; Campbell-Walsh-Wein Urology, p. 2864-2868

🔵 5. TREATMENT OPTIONS

TREATMENT OF RCC
│
├── LOCALIZED DISEASE (T1-T2, N0, M0)
│   │
│   ├── ACTIVE SURVEILLANCE
│   │   └── Small masses (<2 cm), elderly/comorbid patients
│   │       Growth rate ~0.3 cm/year; low metastatic potential if small
│   │
│   ├── SURGICAL (Preferred for fit patients)
│   │   │
│   │   ├── PARTIAL NEPHRECTOMY (PN) ── PREFERRED for T1
│   │   │   ├── Nephron-sparing; equivalent cancer control to radical
│   │   │   ├── Open / Laparoscopic / Robot-assisted
│   │   │   └── Absolute indications: bilateral RCC, solitary kidney
│   │   │       Elective indication: <4 cm tumor, normal contralateral kidney
│   │   │
│   │   └── RADICAL NEPHRECTOMY (RN)
│   │       ├── Removal of kidney + Gerota's fascia ± adrenal ± LN
│   │       ├── Laparoscopic RN = Gold standard for T2 tumors
│   │       └── Indicated: large tumors, central location, not amenable to PN
│   │
│   └── ABLATIVE THERAPIES
│       ├── Radiofrequency Ablation (RFA) ── <3 cm masses
│       ├── Cryoablation ─── <3 cm masses; percutaneous or laparoscopic
│       └── Suitable for elderly/high-surgical-risk patients
│
├── LOCALLY ADVANCED DISEASE (T3-T4 or N1)
│   ├── Radical nephrectomy + IVC thrombectomy (T3b/c)
│   ├── Lymphadenectomy (therapeutic + staging)
│   └── Adjuvant pembrolizumab ── After nephrectomy (high-risk clear cell)
│
└── METASTATIC RCC (mRCC)
    │
    ├── CYTOREDUCTIVE NEPHRECTOMY
    │   └── Selected patients with good PS + limited mets
    │
    ├── TARGETED THERAPY (VEGF/mTOR pathway)
    │   ├── VEGF-TKIs (first-line):
    │   │   ├── Sunitinib
    │   │   ├── Pazopanib
    │   │   ├── Cabozantinib (also inhibits MET + AXL)
    │   │   └── Axitinib (2nd line)
    │   ├── mTOR inhibitors:
    │   │   ├── Temsirolimus (poor-risk)
    │   │   └── Everolimus (2nd line)
    │   └── Bevacizumab + IFN-α (anti-VEGF monoclonal antibody)
    │
    └── IMMUNOTHERAPY (Checkpoint Inhibitors)
        ├── Nivolumab (anti-PD-1) ─── 2nd line
        ├── Nivolumab + Ipilimumab ── 1st line (intermediate/poor-risk)
        ├── Pembrolizumab + Axitinib ─ 1st line
        └── Avelumab + Axitinib ────── 1st line (favorable-risk)

MECHANISM OF CHECKPOINT INHIBITORS:
APC ──► MHC/Antigen ──► TCR → T-cell ACTIVATED
B7 ──────────────────► CD28 → Co-stimulation
B7 ──────────────────► CTLA-4 → INHIBITS T-cell (tumor escape)
PD-L1 (on tumor) ────► PD-1 → INHIBITS T-cell (tumor escape)
Nivolumab blocks PD-1; Ipilimumab blocks CTLA-4 → Restores anti-tumor immunity

• Campbell-Walsh-Wein Urology, p. 2854, 2874-2878

🟣 6. PROGNOSIS & LONG-TERM OUTCOMES

PROGNOSTIC FACTORS IN RCC
│
├── GOOD PROGNOSIS INDICATORS
│   ├── Organ-confined disease (T1/T2)
│   ├── Small tumor size
│   ├── Low nuclear grade (Fuhrman/ISUP Grade 1-2)
│   ├── Chromophobe or papillary subtype
│   ├── Incidental detection
│   └── Complete surgical resection (negative margins)
│
└── POOR PROGNOSIS INDICATORS
    ├── CLINICAL: Poor PS, systemic symptoms, anemia, hypercalcemia,
    │            elevated LDH/ESR/CRP/ALP, thrombocytosis
    ├── ANATOMIC: Large tumor, venous invasion, organ extension,
    │            lymph node metastases, distant metastases (M1)
    └── HISTOLOGIC: High nuclear grade, sarcomatoid features,
                   tumor necrosis, vascular invasion,
                   perinephric/renal sinus fat invasion,
                   positive surgical margins

5-YEAR SURVIVAL BY STAGE:
┌────────────────────────────────────────────┐
│  Stage I (T1, N0, M0)   ──────► ~95%       │
│  Stage II (T2, N0, M0)  ──────► ~75-80%    │
│  Stage III (T3 or N1)   ──────► ~50-60%    │
│  Stage IV (T4 or M1)    ──────► ~10-20%    │
└────────────────────────────────────────────┘

LONG-TERM CONSIDERATIONS:
│
├── SURVEILLANCE AFTER TREATMENT
│   ├── Physical exam + history (every visit)
│   ├── Labs: BUN/Cr, eGFR, urinalysis, CBC, LDH, LFTs, Ca
│   ├── CT chest/abdomen/pelvis (interval depends on stage)
│   └── Bone scan: only if symptoms or elevated ALP
│
├── RENAL FUNCTION MONITORING
│   └── Partial nephrectomy preferred to preserve nephrons
│       PN = equal cancer control + better long-term renal function
│
├── METASTATIC DISEASE OUTCOMES
│   ├── Median OS with modern immunotherapy: ~28-38 months
│   ├── Complete responses possible with IO combinations (~10-16%)
│   └── Selected patients achieve long-term remission
│
└── INTEGRATED PROGNOSTIC MODELS
    ├── MOTZER (MSKCC) Risk Score
    │   Factors: KPS <80%, Hgb <LLN, Ca >ULN, LDH >1.5×ULN, 
    │            no prior nephrectomy
    │   → Favorable / Intermediate / Poor risk groups
    └── SSIGN Score (Mayo Clinic)
        Factors: Stage, Size, Grade, Necrosis
        → Predicts cancer-specific survival

📋 QUICK SUMMARY TABLE

Sources:

• Campbell-Walsh-Wein Urology 3-Volume Set, pp. 2846-2890
• Robbins & Kumar Basic Pathology, pp. 531-533
• NKF Primer on Kidney Diseases, 8th ed., p. 78